Please ensure Javascript is enabled for purposes of website accessibility

bluebird bio Reports Dramatic Improvement in Sickle Cell Patients with LentiGlobin Gene Therapy

By Jim Crumly – Jun 12, 2020 at 1:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Patients in its clinical trial continue to be nearly free of the disease's most serious symptoms.

Gene therapy company bluebird bio (BLUE -0.95%) gave an update on the clinical trial of its treatment for sickle cell disease (SCD) showing that patients in the study have remained free of the most serious symptoms of the disease. The results suggest that Bluebird is on track to submit the treatment to the Food and Drug Administration for accelerated approval by next year.

The report provided updated results from the 25 patients in group C of the study designated HGB-206 given LentiGlobin, a which treats the genetic disease by adding functional copies of a gene into the patient's stem cells, thus enabling them to generate red blood cells capable of producing normal anti-sickling hemoglobin, resulting in a lower proportion of sickled cells.

Sickle-shaped red bloods cells in a blood vessel.

Image source: Getty Images.

The results from the ongoing study continue to show that the treatment almost completely eliminates the most serious manifestation of the disease, vaso-occlusive crises (VOCs), which are painful and life-threatening episodes. Patients in the trial experienced a 99.5% reduction in the annualized rate of VOCs and acute chest syndrome (ACS), which is characterized by cough, chest pain, and low oxygen levels.

An earlier report on this trial in December showcased a marked improvement in VOCs and ACS in patients after they had undergone the company's gene therapy. After those results, Bluebird worked with the FDA to change the primary endpoint of the trial to be the elimination of VOCs as opposed to improvement in hemoglobin measurements, clearing the way for accelerated approval if the patients remained free of the events. The results reported Friday seem to support that outcome, with the company anticipating submitting the drug for FDA approval in the blood disorder in the second half of 2021.

Jim Crumly owns shares of Bluebird Bio. The Motley Fool owns shares of and recommends Bluebird Bio. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$5.71 (-0.95%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.